|
Demographic and clinical parameters
|
All patients (n = 74)
|
Died patients (n = 43)
|
Alive patients (n = 31)
|
p-value
|
|---|
|
Sex (male/female)
|
48/26
|
27/16
|
21/10
|
0.66
|
|
Age (years), mean/range
|
61/23–88
|
64/23–88
|
48/45–78
|
0.001*
|
|
Time from onset of symptoms* to brain imaging (days) mean/range
|
2/1–4
|
2/1–4
|
2/1–4
|
0.58
|
|
Clinical characteristics
| | | | |
|
History of smoking
|
34
|
23 (67.6%)
|
11 (32.3%)
|
0.125
|
|
Obesity
|
12
|
10 (83.3%)
|
2 (16.7%)
|
0.053
|
|
ARDS
|
60
|
29 (48.3%)
|
31 (51.7%)
|
0.0004*
|
|
Medical history
|
59
|
40 (93.02%)
|
19 (61.3%)
|
0.0008*
|
|
Previous neurological illness
|
17
|
8 (47.1%)
|
9 (52.9%)
|
0.292
|
|
Follow-up by CT after 2 days
|
9
|
4 (44.4%)
|
5 (55.6%)
|
0.375
|
|
Clinical manifestation
| | | | |
|
Impaired consciousness
|
22
|
11 (50%)
|
11 (50%)
|
0.357
|
|
Neurological findings
| | | | |
|
Infarction
|
40
|
23 (57.5%)
|
17 (42.5%)
|
0.908
|
|
Hemorrhage and hematomas
|
19
|
12 (63.2%)
|
7 (36.8%)
|
0.604
|
|
PRES
|
3
|
0 (0.0)
|
3 (100%)
|
0.037*
|
|
Cerebral edema
|
2
|
1 (50%)
|
1 (50%)
|
0.813
|
|
WM leucoencephalopathy-related COVID-19
|
3
|
2 (66.7%)
|
1 (33.3%)
|
0.759
|
|
Microhemorrhage
|
3
|
3 (100%)
|
0 (0.0)
|
0.259
|
|
Vascular thrombosis
|
2
|
0 (0.0)
|
2 (100%)
|
0.172
|
|
Acute necrotizing encephalitis
|
2
|
2 (100%)
|
0 (0.0)
|
0.506
|
|
Admission period
| | | | |
|
11–20 days
|
24
|
16 (66.7%)
|
8 (33.3%)
|
0.301
|
- Used tests: Mann–Whitney U test, Chi-square and Fisher exact test *statistically significant (if p < 0.05)
